UNSPSC 51332812: Fluphenazine

This classification denotes an antipsychotic agent with the molecular formula C22H26F3N3OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S79426A41Z, chemically known as 1-piperazineethanol, 4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)- but generally known as fluphenazine, which bears US NIH Compound Identifier 3372. European Medicines Agency schedules Fluphenazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07730MIG.

UNSPSC 51332812 Fluphenazine is a Commodity code that nominally designates a specific antipsychotic pharmaceutical, but recent state and local procurement activity under this code shows little direct relevance to fluphenazine itself. Instead, the code appears to be tagged to broader pharmaceutical procurement initiatives that span multiple drug categories, OTC products, and drug-related public health equipment. State and local governments soliciting under this code are acquiring generic pharmaceuticals, over-the-counter medications, naloxone, and drug deactivation systems through competitive bidding processes and cooperative purchasing frameworks. The issuing bodies include state health agencies (Texas Health and Human Services Commission), county health departments (Seminole County, Florida), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple state and local government facilities). Scope varies significantly: some procurements target narrow annual quantities of specific products with quarterly delivery cycles, while others establish master agreements with multiple authorized wholesalers and seek comprehensive product portfolios across generic and OTC lines.

Geographic activity clusters in Texas, Florida, and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) procurement extending to Oregon and other participating jurisdictions. Representative recent opportunities include Seminole County's IFB60459723LAS (issued Jun 30, 2026, due Jul 26, 2023) for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building; the Texas Health and Human Services Commission's RFI HHS0017013 (posted Apr 3, 2026) exploring direct-to-manufacturer prescription models outside traditional PBM and GPO channels; and MMCAP's RFP S1070000015802 (posted Jan 20, 2026, due Mar 26, 2026) to establish multi-award contracts for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with contract effectiveness July 1, 2026. The MMCAP procurement emphasizes cGMP and Drug Supply Chain Security Act compliance, fixed pricing structures, and administrative fee arrangements, while Seminole County's IFB requires E-Verify compliance and specifies a three-month probationary termination clause. No set-asides are specified in the available documentation.